ISSN 3080-7611(Print)
ISSN 3080-762X(Online)
版权信息 · Copyright

     加入编委 / 副主编 / 同行评议专家
ISSN 3080-7611(Print)
ISSN 3080-762X(Online)

CODEN:ZLYABX
国际标准连续出版物标识符·全球唯一标识符
分配机构:美国化学文摘社(CAS)
DOI前缀:
https://doi.org/10.66106/zlyabx
国图集团 CIBTC
进口备案刊号:G015Z110

索引 检索 存档(Global Indexing)
本刊入选以下全球权威数据库,致力于研究成果的全球化无障碍传播。

CNKI(中国知网,申请中)
CNKI Open(中国知网·开放平台,申请中)
Wanfang Data(万方数据,中国,更新中)
CQVIP(维普期刊网,中国)
CQVIP(中文期刊服务平台,中国)
RCCSE(中国学术期刊目录,武汉大学)
CJWK(长江文库,中国)
BOOKAN(博看,中国)
591adb(中邮阅读·万章期刊,中国)
Baidu Scholar(百度学术,中国)
Baidu Baike(百度百科,中国)
ICI(哥白尼期刊数据库,波兰)
EuroPub(欧洲学术出版数据库,英国)
MDPI scilit(科学与学术数据库,瑞士)
Crossref(交叉引用,美国)
Semantic Scholar(语义学术,美国)
OpenAlex(全球开源学术平台,加拿大)
ACADEMIA.EDU(学术界,美国)
OUCI(开放乌克兰科学,乌克兰)
WorldCat(世界编目数据库,美国)
Scite(智能引文分析数据库,美国)
The Lens(透镜学术,澳大利亚)
OpenAIRE(开放学术发现门户,欧洲)
Google Scholar(谷歌学术,美国)
DOI(数字对象唯一标识符,英国)
Portico(数字存储库,美国)
J-Gate(开放获取期刊门户,印度)
ResearchGate(研究之门,德国)
Research Commons(科睿唯安,美国)
Socolar(开放获取资源检索,中国,更新中)
Sci Online(科学在线,中国澳门)
OALib(开放存取资源图书馆,美国)
EZB(电子期刊图书馆,德国,申请中)
Road(开放科学学术资源,法国)
ISI(国际科学索引平台,阿联酋迪拜)
ASCI(亚洲科学引文索引,美国)
ESJI(欧亚科学期刊索引,哈萨克斯坦)
ResearchBib(研究者索引,日本)
SPI-Hub™(范德比尔特大学,美国)
SJIF(科学期刊影响因子,印度)
RJIF(研究期刊影响因子)
COSMOS(期刊评价指标,印度)
LivRe!(开放期刊门户,巴西)
KIND CONGRESS(阿塞拜疆)
Journament(质量评估与索引)
IP Indexing(ip索引)
Magzter(跨平台数字期刊,美国)
SlideShare(知识共享平台,美国)
SCRIBD(在线图书馆,美国)
Yahoo! Search(雅虎,美国)
Microsoft Bing(微软学术,美国)
LibKey(学术文献快捷获取工具)
R Discovery(研究者发现平台,印度)
Enterscholar(恩特学术)

规划申请

SinoMed 中国生物医学文献服务系统
EBSCO 学术文献数据库(美国)

CABI 国际农业与生物科学中心(英国)
RePEc 经济研究文献数据库(美国)
OAJ 全球OA期刊索引(中国)
DOAJ 开放获取期刊目录(瑞典)
PubMed 医学文摘数据库(美国)
PubMed Central 医学全文数据(美国)
Scopus 爱思唯尔·斯高帕斯(荷兰)
EMBASE 爱思唯尔·医学文摘(荷兰)
ProQuest 科睿唯安(美国)
Research4Life 世界卫生组织数据库

Editing and Publishing
Quest Press Limited
Address
Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Telephone
+853 6881 9699
Email
QuestPress@hotmail.com
Web site
https://zwlc.scionline2025.com
  往期阅览 · All Issues-> 2025年 · 2025  
中外临床医学2025年第1卷第2期第45-49页,pISSN 3080-7611、eISSN 3080-762X 发布者:Quest Press 发布日期:2025/10/19
Open Access 浏览358

 

肺腺癌中的TTF-1、NAPSINA 病理诊断的临床应用效果


潘钰,孙田野,李妍,周萍

1. 泰兴市人民医院 病理科,江苏泰兴,225400;2. 泰兴市人民医院 急诊科,江苏泰兴,225400;3. 泰兴市人民医院 神经内科,江苏泰兴,225400

摘要:目的 分析肺腺癌诊断中应用甲状腺转录因子- 1(TTF - 1) 、天冬氨酸蛋白酶 A(NAPSINA)的临床效果。方法 选择本院2024年1月—12月期间,经手术或者穿刺活检已确诊的120例肺腺癌患者,作为本次实验对象,以病理学组织诊断为金标准,均进行TTF-1(克隆号380)与NAPSINA(克隆号320)的免疫组化检测,评估临床诊断的效果。结果 120例肺腺癌患者中,92例患者的TTF-1表达为阳性,阳性率为76.67%,88 例患者的 NAPSIN A 呈阳性,阳性率73.33%,联合检测阳性例数为110 例,阳性率为91.67%。以病理学为金标准,TTF-1 灵敏度为76.67%,特异度90.00%,准确率为80.00%,阳性预测值94.85%,阴性预测值62.50%;NAPSIN A 对肺腺癌的灵敏度为73.33%,特异性、准确率分别为87.50% 和77.50%,阳性与阴性预测值分别为93.62% 和58.33%;联合组的灵敏度、特异性、准确率分别为91.67%、85.00% 和90.00%,阳性和阴性预测值分别为95.65% 和79.17%,并且与单纯TTF-1 或 NAPSIN A 的检测结果比较,联合组的诊断效果更高,具有统计学意义,(P<0.05)。临床特征分析,不同分化程度与有淋巴结转移的患者中,TTF-1 与NAPSIN A 的阳性表达率,差异有统计学意义(P<0.05)。结论 TTF-1和 NAPSIN A的结合能明显提高肺腺癌细胞的组织学诊断敏感性、准确性、阳性与阴性预测值,对肺腺癌细胞的诊断以及患者的预后,均有重要的指导意义。

关健词:肺腺癌;TTF-1;NAPSINA;病理诊断
Clinical Application of TTF-1 and NAPSINA in Pathological Diagnosis of Lung Adenocarcinoma

Yu Pan,Tianye Sun,Yan Li,Ping Zhou

1.Department of Pathology, Taixing People’s Hospital, Taixing,Jiangsu 225400,China;2.Emergency Department,Taixing People’s Hospital, Taixing,Jiangsu 225400,China;3.Neurology Department,Taixing People’s Hospital, Taixing,Jiangsu 225400,China

Abstract:Objective To evaluate the clinical efficacy of thyroid transcription factor-1 (TTF-1) and aspartate aminotransferaseproteinase A (NAPSINA) in diagnosing lung adenocarcinoma. Methods A total of 120 patients diagnosed with lungadenocarcinoma through surgical resection or biopsy between January and December 2024 were selected as subjects. Immunohistochemicaldetection of TTF-1 (clone 380) and NAPSINA (clone 320) was performed using histopathological diagnosis asthe gold standard to assess diagnostic effectiveness. Results Among the 120 patients, 92 showed positive TTF-1 expression(76.67%), while 88 had positive NAPSINA expression (73.33%). Combined detection identified 110 positive cases (91.67%).Using pathology as the gold standard, TTF-1 demonstrated a sensitivity of 76.67%, specificity of 90.00%, accuracy of 80.00%,positive predictive value (PPV) of 94.85%, and negative predictive value (NPV) of 62.50%. The NAPSIN A showed a sensitivityof 73.33% for lung adenocarcinoma, with specificity and accuracy at 87.50% and 77.50% respectively, corresponding to PPVand NPV of 93.62% and 58.33%. In the combined group, these parameters reached 91.67%,85.00%, and 90.00%, with PPV andNPV of 95.65% and 79.17% respectively. Compared to standalone TTF-1 or NAPSIN A testing, the combined approach showedstatistically significant higher diagnostic efficacy (P<0.05). Clinical characteristic analysis revealed statistically significant differencesin TTF-1 and NAPSIN A positive expression rates between patients with different differentiation grades and lymph nodemetastasis (P<0.05). Conclusion The combination of TTF-1 and NAPSIN A significantly enhances the sensitivity, accuracy,and PPV/NPV of histological diagnosis for lung adenocarcinoma cells, providing important guidance for both clinical diagnosisand patient prognosis.


Keywords : Lung adenocarcinoma; TTF-1; NAPSIN A; Pathological diagnosis
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
版权声明
Copyright Statement
本文采用知识共享“署名 4.0 国际”许可 (CC BY 4.0) 进行许可。许可协议详情请访问: https://creativecommons.org/licenses/by/4.0/
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). For details of the license, please visit:https://creativecommons.org/licenses/by/4.0/.

 
Peer Review
同行评审
Editorial Services
编辑服务
Research Ethics Policy
研究伦理政策
Contributorship & Authorship
贡献者与署名
Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
关于 Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
Global Indexing
全球索引
Copyright Licensing
版权许可
Data Sharing Policy
数据共享政策
Appeal/Correction/Retraction
申诉/更正/撤回
Online Submission
线上投稿
To the Librarian
致图书馆员
Open Access Statement
开放获取声明
Misconduct Handling Policy
处理不端行为政策
Content Licensing
内容许可
Guidelines for Reviewers
审稿人指南
Quality Control Mechanism
质量把控机制
Academic Misconduct Screening Policy
学术不端筛查政策
Advertising Policy
广告政策
Article Processing Charge (APC)
文章处理费
Publication Ethics Policy
出版伦理政策
Joining the Editorial Board, Associate Editors, Peer Reviewers, and Editor-in-Chief
加入编委、副主编、同行评审专家及主编
Quest Press
Bridging Research to a Global Stage.
academia
© 2025-2026 Quest Press Ltd.
Address: Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Tel: +853 6881 9699 / Email: QuestPress@hotmail.com
The QUEST PRESS publishes articles under the following open access license.
Quest Press
is a member of the following organizations.